A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
11/2011
11/17/2011	WO2011141872A1 Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality in patients having a first recurrence of atrial fibrillation or atrial flutter
11/17/2011	WO2011141848A1 Morpholine compounds as mineralocorticoid receptor antagonists
11/17/2011	WO2011141713A1 New bicyclic compounds as pi3-k and mtor inhibitors
11/17/2011	WO2011141474A1 Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
11/17/2011	WO2011141431A1 Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
11/17/2011	WO2011141396A1 Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
11/17/2011	WO2011141387A1 Association of xanthine oxidase inhibitors and statins and use thereof
11/17/2011	WO2011141381A1 Association of xanthine oxidase inhibitors and calcium antagonists and use thereof
11/17/2011	WO2011141188A1 Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
11/17/2011	WO2011141113A2 Combination of vitamin k and nicotinamide
11/17/2011	WO2011140936A1 5,5-disubstituted-2-imino-pyrrolidine derivatives, preparation methods and pharmaceutical uses thereof
11/17/2011	WO2011140832A1 Hexaketide compound and medicinal use thereof
11/17/2011	WO2011140816A1 Thienopyridine ester derivative containing nitrile, preparation method, use and composition thereof
11/17/2011	WO2011140682A1 (2e)-3-phenyl-n-[2,2,2-trifluoro-1-[[(8-quinolineamino)thiomethyl]amino]ethyl]-2-acrylamide and pharmaceutical uses thereof
11/17/2011	WO2011140681A1 Acrylamide compounds and use thereof for inhibiting apoptosis
11/17/2011	WO2011140680A1 Urea compounds and use thereof for inhibiting apoptosis
11/17/2011	WO2011140655A1 Phenolic compositions derived from apple skin and uses thereof
11/17/2011	WO2011113798A3 Inhibitors of semicarabazide - sensitive amine oxidase
11/17/2011	WO2011057243A3 Administration of plant expressed oral tolerance agents
11/17/2011	US20110282464 Reactive Surgical Implants
11/17/2011	US20110281957 Enhanced bioactive formulations of resveratrol
11/17/2011	US20110281951 Compositions and methods for treating amyloidosis
11/17/2011	US20110281945 Gastric acid secretion inhibitor, and potassium channel inhibitor
11/17/2011	US20110281942 Tautomycetin and Tautomycetin Analog Biosynthesis
11/17/2011	US20110281933 Methods and compositions for the management of cardiovascular disease with oligonucleotides
11/17/2011	US20110281928 Process for the preparation of zofenopril and its pharmaceutically acceptable salts thereof
11/17/2011	US20110281925 Dual-acting antihypertensive agents
11/17/2011	US20110281923 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
11/17/2011	US20110281913 Melanocortin receptor antagonist compounds, process for preparing them and use thereof in human medicine and cosmetics
11/17/2011	US20110281891 N-hydroxyamide derivatives and use thereof
11/17/2011	US20110281884 Fused derivatives as pi3kdelta inhibitors
11/17/2011	US20110281880 Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
11/17/2011	US20110281879 Sulfonyl containing compounds as cysteine protease inhibitors
11/17/2011	US20110281878 INHIBITORS OF p38
11/17/2011	US20110281870 Novel substituted octahydrocyclopenta[c]pyrrol-4-amines as calcium channel blockers
11/17/2011	US20110281864 Pyrido[3,2-d]Pyridazine-2(1H)-One Compounds as p38 Modulators and Methods of Use Thereof
11/17/2011	US20110281859 Novel heterocyclic compounds as metap-2 inhibitors
11/17/2011	US20110281857 Pi3k/mtor kinase inhibitors
11/17/2011	US20110281854 Morpholine compounds
11/17/2011	US20110281853 Compositions and methods for treating or preventing atrial fibrillation
11/17/2011	US20110281848 Imidazole compounds having pharmaceutical activity towards the sigma receptor
11/17/2011	US20110281846 Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
11/17/2011	US20110281843 Substituted indazole derivatives active as kinase inhibitors
11/17/2011	US20110281841 Kinase Inhibitors
11/17/2011	US20110281840 N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity
11/17/2011	US20110281837 3-substituted-6-aryl pyridines
11/17/2011	US20110281836 Silent desensitizers of neuronal NACHR and methods of use thereof
11/17/2011	US20110281832 Organic compounds
11/17/2011	US20110281828 Substituted oxazolidinone derivatives
11/17/2011	US20110281826 Stilbene derivatives for adp-ribosyl cyclase inhibitors
11/17/2011	US20110281825 Inositol pyrophosphates, and methods of use thereof
11/17/2011	US20110281823 Pharmaceutical preparation containing an angiotensin II Receptor antagonist, a calcium channel blocker and polyvinyl alcohol
11/17/2011	US20110281822 Aromatic compounds having sphingosine-1-phosphonate (s1p) receptor activity
11/17/2011	US20110281812 Compounds
11/17/2011	US20110281811 Use Of Leukotriene Inhibitors For Treating Lung Diseases In Prematurely Born Infants
11/17/2011	US20110281801 Prediction and prevention of preeclampsia
11/17/2011	US20110281793 Method For Reducing Cardiovascular Morbidity And Mortality In Prediabetic Patients And Patients With Type 2 Diabetes
11/17/2011	US20110280971 Berry oils and products
11/17/2011	US20110280966 Dosing regimens and methods of treatment using carbon monoxide
11/17/2011	US20110280951 Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome
11/17/2011	US20110280927 Composition and dressing with nitric oxide
11/17/2011	US20110280887 Methods for diagnosis of cardiovascular disease
11/17/2011	US20110280876 Mutated netrin - 4, fragments thereof and their use as medicines
11/17/2011	US20110280873 MCP1-Ig FUSION VARIANTS
11/17/2011	US20110280872 Methods for prevention and treatment of inflammation using anti-chemokine antibodies
11/17/2011	US20110280871 Methods for prevention and treatment of inflammation using anti-chemokine antibodies
11/17/2011	US20110280867 Heterocyclic aspartyl protease inhibitors
11/17/2011	US20110280845 Treatment of rheumatoid arthritis using placental stem cells
11/17/2011	US20110280834 Methods and compositions for cardiac tissue regeneration
11/17/2011	US20110280832 Eotaxin-2 (ccl24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders
11/17/2011	US20110280830 Albumin Fusion Proteins
11/17/2011	US20110280825 Extracorporeal devices and methods of treating complications of pregnancy
11/17/2011	US20110280800 Il-1 binding proteins
11/17/2011	DE102010028874A1 Isolating stilbenoid with solvent immiscible in water, useful for producing cosmetics, food, dietary supplements, pharmaceuticals and animal feed, comprises reducing the water content of the solvent
11/17/2011	CA2835596A1 Benzo- or pyrido-imidazole derivative
11/17/2011	CA2798895A1 Modulation of splenocytes in cell therapy
11/17/2011	CA2798874A1 Phenolic compositions derived from apple skin and uses thereof
11/17/2011	CA2798831A1 Morpholine compounds as mineralocorticoid receptor antagonists
11/16/2011	EP2386566A2 Chi-conotoxin peptides (II)
11/16/2011	EP2386565A2 Compounds and methods to inhibit or augment an inflammatory response
11/16/2011	EP2386556A1 Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands
11/16/2011	EP2386546A1 Novel pyrazole-3-carboxamide derivate having 5-ht2b receptor antagonist activity
11/16/2011	EP2386545A1 Heteroaryl ureas containing nitrogen hetero-atoms as P38 kinase inhibitors
11/16/2011	EP2386539A2 Modified lysine-mimetic compounds
11/16/2011	EP2386319A1 Promoters exhibiting endothelial cell specificity and methods of using same
11/16/2011	EP2386317A1 Methods for treating conditions associated with MASP-2 dependent complement activation
11/16/2011	EP2386316A1 Methods for treating conditions associated with MASP-2 dependent complement activation
11/16/2011	EP2386315A1 Methods for treating conditions associated with MASP-2 dependent complement activation
11/16/2011	EP2386311A1 Compositions for improving lipid metabolism
11/16/2011	EP2386310A2 Methods for preserving organs and tissues
11/16/2011	EP2386305A2 Selective Estrogen Receptor Modulator in Combination With Dehydroepiandrosterone (DHEA) or Analogues
11/16/2011	EP2386304A2 Selective Estrogen Receptor Modulator in Combination With Dehydroepiandrosterone (DHEA) or Analogues
11/16/2011	EP2386301A1 Pharmaceutical composition of levoamlodipine or pharmaceutically acceptable salts thereof and blockers, and use thereof
11/16/2011	EP2386300A1 Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality in patients having a first recurrence of atrial fibrillation or atrial flutter
11/16/2011	EP2385942A1 Benzimidazole and pyrazolopyridine derivatives for treating and/or preventing cardiovascular diseases
11/16/2011	EP2385840A1 Materials and methods for the treatment of hypertension
11/16/2011	EP2225243B1 Derivatives of N-heterocyclic-6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof
11/16/2011	EP2125785B1 Indole-3-yl-carbonyl-piperidine- derivatives for the treatment of anxiety and depressive disorders via v1a receptor antagonism
11/16/2011	EP2103630B1 Preparation of low bleeding anticoagulant fusion protein and its use
11/16/2011	EP1931676B1 Pyrazolopyrimidines as protein kinase inhibitors

1 ... 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 ... 1595